New molecular targets in meningiomas: the present and the future

Vyshak Alva Venur, Sandro Santagata, Evanthia Galanis, Priscilla K. Brastianos

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

RECENT FINDINGS: Many of the recently discovered genetic alterations correlate with distinct clinical phenotypes. SMO, AKT and PIK3CA mutations are enriched in the anterior skull base. KLF4 mutations are specific for secretory histology, and BAP1 alterations are common in progressive rhabdoid meningiomas. Alterations in TERT, DMD and BAP1 correlate with poor clinical outcomes. Importantly, the discovery of clinically actionable alterations in a number of genes, including SMO, AKT1 and PIK3CA, has opened up novel potential avenues for therapeutic management of meningiomas. Overexpression of PD-L1 in higher grade meningiomas also provides preclinical support for the investigation of checkpoint blockade.

PURPOSE OF REVIEW: Meningiomas, the most common primary brain tumor, have historically been managed with surgery and radiation. Traditional chemotherapy has not been effective. Fortunately, recent advances in genetic sequencing have led to an improved understanding of the molecular drivers in meningioma. This article aims to discuss the diagnostic and therapeutic implications of recently discovered genetic alterations in meningiomas.

SUMMARY: The discovery of genetic alterations has improved our understanding of the natural history and classification of meningiomas. Clinical trials with several novel agents targeting driver mutations are currently accruing patients and they can lead to better treatment strategies.

Original languageEnglish (US)
Pages (from-to)740-746
Number of pages7
JournalCurrent Opinion in Neurology
Volume31
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

Meningioma
Mutation
Skull Base
Natural History
Brain Neoplasms
Histology
Therapeutics
Clinical Trials
Radiation
Phenotype
Drug Therapy
Genes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

New molecular targets in meningiomas : the present and the future. / Venur, Vyshak Alva; Santagata, Sandro; Galanis, Evanthia; Brastianos, Priscilla K.

In: Current Opinion in Neurology, Vol. 31, No. 6, 01.12.2018, p. 740-746.

Research output: Contribution to journalArticle

Venur, Vyshak Alva ; Santagata, Sandro ; Galanis, Evanthia ; Brastianos, Priscilla K. / New molecular targets in meningiomas : the present and the future. In: Current Opinion in Neurology. 2018 ; Vol. 31, No. 6. pp. 740-746.
@article{0e268a480a3149669c99d6691947e475,
title = "New molecular targets in meningiomas: the present and the future",
abstract = "RECENT FINDINGS: Many of the recently discovered genetic alterations correlate with distinct clinical phenotypes. SMO, AKT and PIK3CA mutations are enriched in the anterior skull base. KLF4 mutations are specific for secretory histology, and BAP1 alterations are common in progressive rhabdoid meningiomas. Alterations in TERT, DMD and BAP1 correlate with poor clinical outcomes. Importantly, the discovery of clinically actionable alterations in a number of genes, including SMO, AKT1 and PIK3CA, has opened up novel potential avenues for therapeutic management of meningiomas. Overexpression of PD-L1 in higher grade meningiomas also provides preclinical support for the investigation of checkpoint blockade.PURPOSE OF REVIEW: Meningiomas, the most common primary brain tumor, have historically been managed with surgery and radiation. Traditional chemotherapy has not been effective. Fortunately, recent advances in genetic sequencing have led to an improved understanding of the molecular drivers in meningioma. This article aims to discuss the diagnostic and therapeutic implications of recently discovered genetic alterations in meningiomas.SUMMARY: The discovery of genetic alterations has improved our understanding of the natural history and classification of meningiomas. Clinical trials with several novel agents targeting driver mutations are currently accruing patients and they can lead to better treatment strategies.",
author = "Venur, {Vyshak Alva} and Sandro Santagata and Evanthia Galanis and Brastianos, {Priscilla K.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/WCO.0000000000000615",
language = "English (US)",
volume = "31",
pages = "740--746",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - New molecular targets in meningiomas

T2 - the present and the future

AU - Venur, Vyshak Alva

AU - Santagata, Sandro

AU - Galanis, Evanthia

AU - Brastianos, Priscilla K.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - RECENT FINDINGS: Many of the recently discovered genetic alterations correlate with distinct clinical phenotypes. SMO, AKT and PIK3CA mutations are enriched in the anterior skull base. KLF4 mutations are specific for secretory histology, and BAP1 alterations are common in progressive rhabdoid meningiomas. Alterations in TERT, DMD and BAP1 correlate with poor clinical outcomes. Importantly, the discovery of clinically actionable alterations in a number of genes, including SMO, AKT1 and PIK3CA, has opened up novel potential avenues for therapeutic management of meningiomas. Overexpression of PD-L1 in higher grade meningiomas also provides preclinical support for the investigation of checkpoint blockade.PURPOSE OF REVIEW: Meningiomas, the most common primary brain tumor, have historically been managed with surgery and radiation. Traditional chemotherapy has not been effective. Fortunately, recent advances in genetic sequencing have led to an improved understanding of the molecular drivers in meningioma. This article aims to discuss the diagnostic and therapeutic implications of recently discovered genetic alterations in meningiomas.SUMMARY: The discovery of genetic alterations has improved our understanding of the natural history and classification of meningiomas. Clinical trials with several novel agents targeting driver mutations are currently accruing patients and they can lead to better treatment strategies.

AB - RECENT FINDINGS: Many of the recently discovered genetic alterations correlate with distinct clinical phenotypes. SMO, AKT and PIK3CA mutations are enriched in the anterior skull base. KLF4 mutations are specific for secretory histology, and BAP1 alterations are common in progressive rhabdoid meningiomas. Alterations in TERT, DMD and BAP1 correlate with poor clinical outcomes. Importantly, the discovery of clinically actionable alterations in a number of genes, including SMO, AKT1 and PIK3CA, has opened up novel potential avenues for therapeutic management of meningiomas. Overexpression of PD-L1 in higher grade meningiomas also provides preclinical support for the investigation of checkpoint blockade.PURPOSE OF REVIEW: Meningiomas, the most common primary brain tumor, have historically been managed with surgery and radiation. Traditional chemotherapy has not been effective. Fortunately, recent advances in genetic sequencing have led to an improved understanding of the molecular drivers in meningioma. This article aims to discuss the diagnostic and therapeutic implications of recently discovered genetic alterations in meningiomas.SUMMARY: The discovery of genetic alterations has improved our understanding of the natural history and classification of meningiomas. Clinical trials with several novel agents targeting driver mutations are currently accruing patients and they can lead to better treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=85055845748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055845748&partnerID=8YFLogxK

U2 - 10.1097/WCO.0000000000000615

DO - 10.1097/WCO.0000000000000615

M3 - Article

C2 - 30379704

AN - SCOPUS:85055845748

VL - 31

SP - 740

EP - 746

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 6

ER -